2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
3
Leukemia
3
Vomiting
2
Stomach Neoplasms
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Motor Activity
2
Ventilator-Induced Lung Injury
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Substance-Related Disorders
1
Solid Tumors
1
Recurrence
1
Postoperative Complications
1
Pituitary Neoplasms
1
Pancreatic Neoplasms
1
Opioid-Related Disorders
1
Opioid-Induced Constipation
1
Neurofibromatosis 1
1
Neoplasms
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Gemcitabine
9
pembrolizumab
7
Cisplatin
5
enfortumab vedotin
4
atezolizumab
4
Trastuzumab
4
Mitomycin
4
Carboplatin
4
Sunitinib
3
Pemetrexed
3
dodecyl maltoside
2
cabozantinib
2
Water
2
Sugammadex
2
Standard of Care
2
Saline Solution
2
Paclitaxel
2
Nivolumab
2
Neostigmine
2
Docetaxel
2
Cetuximab
2
Bevacizumab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
vinflunine
1
valrubicin
1
tucatinib
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Dosage Forms
×
Clear all
NCT04644432
2020-11-25
INDIGO
Herlev and Gentofte Hospital
Phase 2
Unknown
30 enrolled